The performance of the MUC16/WFDC2 combination marker clearly varied with ovarian cancer histology: the percentage of cases correctly classified was 86% (38/44) for serous cases, 83% (5/6) for endometrioid cases, 17% (1/6) for mucinous cases and 0% (0/5) for clear cell cases (Table 5). This evidence concerns the gene WFDC2 and ovarian carcinoma.